NUVB
Overvalued by 92.3% based on the discounted cash flow analysis.
Market cap | $807.76 Million |
---|---|
Enterprise Value | $801.86 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.35 |
Beta | 1.36 |
Outstanding Shares | 273,565,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.23 |
---|---|
PEG | -1.12 |
Price to Sales | - |
Price to Book Ratio | 2.29 |
Enterprise Value to Revenue | 330.53 |
Enterprise Value to EBIT | -5.96 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | 0.05 |
No data
No data
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...